Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07732361) titled 'A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT)' on July 23.
Study Type: Observational
Primary Sponsor: Alexion Pharmaceuticals, Inc.
Condition:
Thrombotic Microangiopathy
Hematopoietic Stem Cell Transplant
Recruitment Status: Not recruiting
Date of First Enrollment: January 22, 2025
Target Sample Size: 307
Countries of Recruitment:
United States
Belgium
Brazil
France
Greece
Italy
Japan
South Korea
Spain
United Kingdom
Belgium
Brazil
France
Greece...